文献速递皮肤肿瘤

基底细胞癌PD-L1表达与既往治疗方式数量的关联

Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
PubMed 文献 · JAMA Dermatol · 2017-01-01

单中心横断面研究纳入62例患者共138个基底细胞癌(BCC)标本,免疫组化检测PD-L1表达。89.9%肿瘤细胞和94.9%肿瘤浸润淋巴细胞(TILs)PD-L1阳性。提示PD-1免疫治疗可能对BCC有活性,需临床试验验证。

要点

  • 多数BCC肿瘤细胞和TILs表达PD-L1(阳性率分别为89.9%和94.9%)。
  • 经治疗BCC的PD-L1染色强度显著高于未治疗BCC。
  • PD-L1强度随既往治疗方式数量增加而升高。

核心结论

  • PD-1免疫治疗可能对BCC有活性,包括既往治疗过的BCC,但需未来临床试验验证。

研究设计与样本

  • 单中心学术三级转诊中心横断面研究,纳入62例患者共138个福尔马林固定BCC标本,免疫组化染色由皮肤病理学家和皮肤科医生盲法判读,研究日期为2014年3月31日至2016年6月7日。

主要发现

  • 138个BCC中,89.9%(124/138)肿瘤细胞PD-L1阳性,94.9%(131/138)TILs PD-L1阳性,阳性定义为相应细胞群中免疫组化染色大于5%。

临床怎么用

  • 对既往多线治疗后的BCC,可考虑评估PD-L1表达作为潜在免疫治疗依据,但目前证据仅来自横断面研究,尚不能常规推荐。

局限性

  • 原文未明确报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Response to programmed death 1 (PD-1) inhibitors has been associated with programmed death ligand 1 (PD-L1) expression levels in several cancers, but PD-L1 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date. OBJECTIVE: To assess PD-L1 expression in treatment-naive and treated BCCs. DESIGN, SETTING, AND PARTICIPANTS: This investigation was a cross-sectional study at a single academic tertiary referral center. Immunohistochemical staining on formalin-fixed BCCs from a dermatology clinic were examined in masked fashion by a dermatopathologist and a dermatologist. The study dates were March 31, 2014, to June 7, 2016. EXPOSURES: Treated BCCs (including those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treatment-naive BCCs. MAIN OUTCOMES AND MEASURES: Percentage of tumor cells and tumor-infiltrating lymphocytes (TILs) with PD-L1 expression, intensities of expression, and association with treatment modalities. RESULTS: Among 138 BCCs from 62 patients (43 males and 19 females; mean [SD] age at biopsy, 61.6 [13.7] years), 89.9% (124 of 138) were positive for PD-L1 expression in tumor cells, and 94.9% (131 of 138) were positive for PD-L1 expression in TILs, defined as greater than 5% positive immunohistochemical staining in the respective cell populations. The PD-L1 immunohistochemical staining intensity of 78 treated BCCs compared with 60 treatment-naive BCCs was significantly different in tumor cells (32% vs 7%, P = .003) and TILs (47% vs 18%, P = .008) after adjusting for the age at diagnosis. In a multivariable model adjusting for age, sex, and BCC location, PD-L1 staining intensity in tumor cells increased with the number of distinct prior treatment modalities (median, 0.12; interquartile range, 0.03-0.20; P = .007). CONCLUSIONS AND RELEVANCE: Our data suggest that PD-1 immunotherapy may have activity against BCCs, including in those that have been previously treated. This hypothesis needs to be tested in future clinical trials.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Chang J, Zhu GA, Cheung C, et al. Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. JAMA Dermatol. 2017. PMID: 28259105. doi:10.1001/jamadermatol.2016.5062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。